S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Enanta Pharmaceuticals Stock Forecast, Price & News

-0.60 (-1.05%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
226,997 shs
Average Volume
215,471 shs
Market Capitalization
$1.15 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Enanta Pharmaceuticals logo

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.


What 10 Analyst Ratings Have To Say About Enanta Pharmaceuticals
January 13, 2022 |  markets.businessinsider.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $80.00
January 13, 2022 |  americanbankingnews.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Down 3.9%
January 11, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$97.07 million
Book Value
$19.76 per share


Net Income
$-79 million
Pretax Margin




Free Float
Market Cap
$1.15 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.47 out of 5 stars

Medical Sector

152nd out of 1,418 stocks

Pharmaceutical Preparations Industry

63rd out of 684 stocks

Analyst Opinion: 4.3Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

Is Enanta Pharmaceuticals a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Enanta Pharmaceuticals stock.
View analyst ratings for Enanta Pharmaceuticals
or view top-rated stocks.

How has Enanta Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ENTA shares have increased by 6.7% and is now trading at $56.49.
View which stocks have been most impacted by COVID-19

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, February 14th 2022.
View our earnings forecast for Enanta Pharmaceuticals

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its earnings results on Monday, November, 22nd. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.31) by $0.09. The biotechnology company earned $23.58 million during the quarter, compared to analyst estimates of $35.65 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 18.53% and a negative net margin of 81.38%. During the same quarter last year, the company earned ($0.55) EPS.
View Enanta Pharmaceuticals' earnings history

What price target have analysts set for ENTA?

8 brokers have issued twelve-month target prices for Enanta Pharmaceuticals' shares. Their forecasts range from $55.00 to $130.00. On average, they expect Enanta Pharmaceuticals' stock price to reach $90.25 in the next twelve months. This suggests a possible upside of 59.8% from the stock's current price.
View analysts' price targets for Enanta Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the following people:
  • Jay R. Luly, President, Chief Executive Officer & Director
  • Paul J. Mellett, CFO & Senior VP-Finance & Administration
  • Yat Sun Or, CSO, Senior Vice President-Research & Development
  • Nathalie Adda, Chief Medical Officer & Senior Vice President (LinkedIn Profile)
  • Nathaniel S. Gardiner, Secretary, Senior Vice President & General Counsel

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

3 employees have rated Enanta Pharmaceuticals CEO Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among Enanta Pharmaceuticals' employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.10%) and State of Alaska Department of Revenue (0.06%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda and Paul J Mellett.
View institutional ownership trends for Enanta Pharmaceuticals

Which major investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., and State of Alaska Department of Revenue. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, and Nathalie Adda.
View insider buying and selling activity for Enanta Pharmaceuticals
or view top insider-selling stocks.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $56.49.

How much money does Enanta Pharmaceuticals make?

Enanta Pharmaceuticals has a market capitalization of $1.15 billion and generates $97.07 million in revenue each year. The biotechnology company earns $-79 million in net income (profit) each year or ($3.91) on an earnings per share basis.

How many employees does Enanta Pharmaceuticals have?

Enanta Pharmaceuticals employs 141 workers across the globe.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is www.enanta.com.

Where are Enanta Pharmaceuticals' headquarters?

Enanta Pharmaceuticals is headquartered at 500 ARSENAL STREET, WATERTOWN MA, 02472.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at (617) 607-0800, via email at [email protected], or via fax at 617-607-0530.

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.